Leading the way to safer medication
 Crosscheck  Recommender

Bevacizumab

Description

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

ATC Classification

Code
Title
Category
L01XC07
Bevacizumab
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XC Monoclonal antibodies

Trade names

Trade name
Countries

Austria Canada Cyprus France Netherlands

Austria France

Austria

Australia Austria Canada Netherlands United States

Austria

Austria Canada Netherlands United States

Product Monographs

Monograph
Type
Country
AVASTIN Concentrate for solution for infusion
MPI, EU: SmPC